Table 1.
Table of mentioned systematic reviews, meta-analyses and important studies.
| Name/Reference | Type | Year | RCTs/Studies | Patients | Treatment/Intervention/Measurement | Outcomes |
|---|---|---|---|---|---|---|
| Lunn et al. [35] | SR | 2014 | 18 | 6407 | Duloxetine: 60, 120 mg/day | Primary: Short-term improvement in pain |
| Secondary: Long-term improvement in pain, improvement in quality of life score, patient-reported pain, adverse effects during treatment | ||||||
| Yuan-Chun Ko et al. [36] | SR and MA | 2021 | 3 | 290 | Duloxetine: 20–80 mg/day Gabapentin: 300–1200 mg/day |
Primary: VAS (Visual Analogue Scale) Secondary: Sleep Interference Score, Clinical Global Impression of Change, Patient Global Impression of Change, DN Symptom Score, DN Examination Score, Neuropathic Disability score |
| Chung-Sheng Wu et al. [37] | SR and MA | 2023 | 7 | 2205 | Duloxetine: 20–120 mg/day | Pain improvement, patient-reported health performance and quality of life |
| Andreas Limpas et al. [38] | SR | 2021 | 83 | / | Anticonvulsants, SNRIs, TCAs, opioids, topical treatment, cannabinoids, monoclonal antibodies, botulinum toxin, other | / |
| Floortje van Nooten et al. [39] | SR and MA | 2017 | 24 | 5870 | Capsaicin 8% | At least 30% pain reduction, at least 50% pain reduction, tolerability |
| Aaron Vinik et al. [40] | R, DB, Comparator-Controlled Study | 2014 | / | 452 | Mirogabalin: 5–30 mg/day | Primary: ADPS (Average Daily Pain Score) change from baseline Secondary: Characterizing dose response, incidence of responders, comparing effects of mirogabalin to pregabalin, assessing time to meaningful pain relief |
| Masayuki Baba et al. [41] | RA, DB, PC Study | 2019 | / | 834 | Mirogabalin: 15–30 mg/day | Efficacy, safety, and tolerability |
| Titas Buksnys et al. [42] | SR and MA | 2020 | 43 | / | Lidocaine medicated plaster 700 mg | Efficacy, adverse effects |
| Moisset et al. [43] | SR | 2020 | 131 | / | TCAs, SNRIs, antiepileptics, opioids, topical agents, cannabinoids, ketamine, other | Comprehensive assessment of all therapies for neuropathic pain treatment |
| Farag Hussein et al. [44] | SR and MA | 2022 | 36 | 11,930 | Duloxetine: 60 and 120 mg/day Pregabalin: 150–600 mg/day Milnacipran: 100 and 200 mg/day Amitriptyline |
Comparative effectiveness and acceptability of medication for pain, sleep, depression, fatigue, and quality of life |
| Nanna Finnerup et al. [45] | SR and MA | 2015 | 229 | / | TCAs, SNRIs, antiepileptics, opioids, oromucosal cannabinoids, topical lidocaine, capsaicin patches, other | Individual and combined number needed to treat and number needed to harm values |
| Solomon Tesfaye et al. [46] | R, DB, Multicenter, Crossover Trial | 2022 | / | 130 | Primary: Difference in 7-day average NRS (Numerical Rating Scale) daily pain Secondary: HADS (Hospital Anxiety and Depression Scale), proportion of patients achieving 30% and 50% pain reduction from baseline, ISI (Insomnia Severity Index), NPSI (Neuropathic Pain Symptom Inventory), other |
|
| Zin Zin Htike et al. [47] | SR and Mixed-Treatment Comparison Analysis | 2017 | 34 | 14,464 | Glucagon-like peptide-1 receptor agonist (GLP-1ARs): albiglutide, dulaglutide, exenatide, liraglutide, others | Glycemic control, body weight, blood pressure and lipid profile, gastrointestinal and other side effects |
| Donna Shu-Han Lin et al. [48] | Retrospective Cohort | 2022 | / | 101,440 | Glucagon-like peptide-1 receptor agonist (GLP-1ARs); Sodium-glucose cotransporter 2 inhibitors (SGLT2is) | Primary: Major adverse limb events (MALE) Secondary: Major adverse cardiac events (MACE), death from any cause, hospitalization due to heart failure |
| Tuan Dinh Le et al. [49] | Cross-sectional | 2022 | / | 473 | GLP-1 serum levels | Prevalence of DPN and its risk factors, relation between DPN and fasting GLP-1 levels |
| Steven Marso et al. [50] | R, DB Trial | 2016 | / | 9340 | Liraglutide 1.8 mg/day | Fist occurrence of death from cardiovascular causes, non-fatal MI, or non-fatal stroke, microvascular outcomes (renal and retinal), neoplasms, pancreatitis |
| Steven Marso et al. [51] | R, DB Trial | 2016 | / | 3297 | Semaglutide 0.5 or 1.0 mg/week | Fist occurrence of death from cardiovascular causes, non-fatal MI, or non-fatal stroke, microvascular outcomes (renal and retinal) |
| Tushar Issar et al. [52] | Cross-sectional | 2021 | / | 90 | GLP-1RA, DPP-4i, SGLT-2i | Improvement in nerve excitability |
SA—systematic analysis; MA—meta-analysis; R—randomized; DB—double-blind; PC—placebo-controlled.